EUCTR2015-001617-27-NL进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, multicentre proof-of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis - IVA337 SSC POC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Systemic sclerosis according to ACR/EULAR 2013 criteria
- •Diffuse cutaneous SSc subset (LeRoy’s criteria)
- •Diagnosis within the past 3 years as defined by the first non-Raynaud’s symptom
- •MRSS between 10 and 25
- •Aged between 18 and 75 years
- •Informed consent documented by signature
- •Patients on stable treatment (for >3 months) with prednisone = 10 mg, methotrexate= 20 mg/w, azathioprine = 150 mg/d, mycophenolate mofetil = 2g/d, or leflunomide = 20 mg/d may be included in the study; the therapy must be maintained as background therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 135
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •Cyclophosphamide during the past 3 months
- •Requirement of IV prostanoids for critical ischemia or pulmonary hypertension in the last 3 months
- •Renal insufficiency defined by a creatinine clearance of less than 30 ml/min (CKD-EPI or MDRD formula) and/or past/current renal crisis
- •Hepatic impairment i.e. primary biliary cirrhosis and unexplained persistent liver function abnormality,
- •Gallbladder disease (Cholelithiasis is not an exclusion criterion)
- •Diabetic ketoacidosis
- •Severe cardiac (LVEF <45%) and/or pulmonary disease (FVC < 50% or pulmonary hypertension proven by right heart catheterisation)
- •History of heart failure, symptomatic coronary artery disease, significant ventricular tachyarrhythmia, stent placement, coronary artery bypass surgery, and/or myocardial infarction.
- •Recipient of solid organ transplant
- •Gastrointestinal involvement preventing oral administration of study drug
- •Chronic infections, positive serology for infection with hepatitis B or C.
- •Pregnancy, Lactation. Woman of childbearing potential unwilling to use a medically acceptable form of birth control
- •History of malignancy within the last 5 years, except for resected basal or squamous cell carcinoma of the skin, treated cervical dysplasia, or treated in situ cervical cancer
- •A recent history of alcohol or drug abuse, non-compliance with other medical therapies
- •Participation in a clinical study involving another investigational drug or device within the past 4 weeks or during the studyg
- •Laboratory parameters at the pre-treatment visit showing any of the following abnormal results: transaminases > 2x the upper limit of normal (ULN) and/or bilirubin > 2x ULN; neutrophil count < 1,500/mm3; platelet count < 100,000/mm3; haemoglobin < 9 g/dL
- •Known hypersensitivity or allergy to class of drugs or the investigational product
- •Any condition or treatment, which in the opinion of the investigator, places the subject at unacceptable risk as a patient in the trial
- •Co-therapy with biologics. Wash-out period: Any anti-TNF agent in the last 3-months: adalimumab, certolizumab, etanercept, golimumab, infliximab; abatacept in the last 3 months; rituximab in the last 6 months
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® Depot and RAD001 10 mg/d or Sandostatin LAR® Depot and placebo - N/Aow grade neuroendocrine carcinoma consists of carcinoid and pancreatic endocrine tumors. These tumors originate from the neuroendocrine cells throughout the body and are capable of producing various peptides. Their clinical course is often indolent but can also be highly aggressive and resistant to therapy. Current treatments for bulky metastatic tumors have either low biologic activity, high unfavorable toxicity profile or both.MedDRA version: 8.1Level: LLTClassification code 10007276Term: Carcinoid tumour NOSEUCTR2006-004507-18-FIovartis Pharma Services AG390
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter parallel-group dose ranging clinical trial to assess the efficacy and safety of Org 4419-2 in the treatment of obstructive sleep apnea/hypopnea syndromeEUCTR2005-000733-37-SEV Organon100
进行中（未招募）
1 期
A trial to learn more about how BAY 2327949 works and how safe it is in participants with chronic kidney diseaseMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersChronic Kidney DiseaseEUCTR2020-002192-35-FIBayer - AG120
进行中（未招募）
1 期
Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS)Amyotrophic lateral sclerosis (ALS)MedDRA version: 14.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-022818-19-BEBiogen Idec Limited915
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of methotrexate (MTX) in patients with active rheumatoid arthritis who are inadequate responders to MTX therapy - MOBILITYMedDRA version: 12.0Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2009-016266-90-CZSanofi-aventis Recherche & Développement1,740